From: Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia
Adverse Event
Placebo
BUDCA Dose
500 mg/day
1000 mg/day
2000 mg/day
Number of Subjects
12
14
Headache
5
4
3
Dizziness
0
2
Nausea
1
Flatulence
Anorexia